NCT00864851View on ClinicalTrials.gov

Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 29, 2008

Primary Completion Date

June 1, 2012

Study Completion Date

July 5, 2012

Conditions
Fabry Disease
Interventions
BIOLOGICAL

Replagal

Intravenous (IV) infusion for 12 months

Trial Locations (12)

3052

The Royal Melbourne Hospital, Parkville

10016

New York Unversity School of Medicine, New York

22152

O & O Alpan, LLC, Springfield

52242

University of Iowa Hospitals and Clinics, Iowa City

85719

AKDHC Tucson Access Center, Tucson

128 OO

The Charles University Hospital, Prague

FI-20520

Turku University Central Hospital, Turku

Unknown

Gobemador Irala y Coronel Lopez - Barrio Sojania, Asunción

31-066

Szpital Uniwersytecki w Krakowie, Krakow

04-628

Instytut Kardiologii, Warsaw

SI 2380

General Hospital Slovenj Gradec, Slovenj Gradec

M6 8HD

Salford Royal NHS Foundation Trust, Salford

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT00864851 - Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease | Biotech Hunter | Biotech Hunter